MWNA
PTLA

Marshall Wace North America’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Marshall Wace North America’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,257
Closed -$23K – 1622
2020
Q1 		$23K Sell
3,257
-64,604
-95% -$806K ﹤0.01% 1129
2019
Q4 		$1.62M Buy
+67,861
New +$1.87M 0.01% 617
2019
Q1 		– Sell
-4,096
Closed -$80K – 2059
2018
Q4 		$80K Buy
+4,096
New +$84.2K ﹤0.01% 1132
2017
Q3 		– Sell
-24,471
Closed -$1.37M – 1619
2017
Q2 		$1.37M Buy
+24,471
New +$980K 0.01% 838

Other funds holding PTLA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Marshall Wace North America's PTLA Position: Q2 2020 in Review

Marshall Wace North America sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2020, closing a stake of 3,257 shares — an estimated $23K sold.

Marshall Wace North America first reported a position in PTLA in Q2 2017 and held it in 4 quarters. The position peaked at $1.62M in Q4 2019. 162 funds tracked by Wall St. Rank hold PTLA as of Q2 2020.

  • Marshall Wace North America reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • Marshall Wace North America sold 3,257 Portola Pharmaceuticals, Inc. shares in Q2 2020, an estimated $23K.
  • Marshall Wace North America first reported a position in Portola Pharmaceuticals, Inc. in Q2 2017 and held it in 4 quarters.
  • Marshall Wace North America's Portola Pharmaceuticals, Inc. position peaked at $1.62M in Q4 2019.
  • 162 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2020.

Based on Marshall Wace North America's 13F filing for Q2 2020, filed 13 Aug 2020.